STAT

Opinion: Amid the Covid-19 pandemic, it is time for biomedical research investments to pay off

Every month of the Covid-19 lockdown costs about $1 trillion. Eliminating the pandemic's threat to public health, the economy, and our way of life will be the best return on…
Cell culture technician Raychel Lewis sets up equipment to test Covid-19 samples from recovered patients at Mirimus lab in Brooklyn, New York.

The Covid-19 pandemic is the monumental public health challenge the medical community has been fearing the past few decades. The price of this disease should convince Americans of the wisdom of our investment in biomedical research. If we seize the opportunity and capitalize on it, that investment will pay dividends.

As policymakers invest more than $2 trillion to stave off the economic impacts of the pandemic in the United States, the health sector is frantically working to treat the ill, discover effective treatments for the virus, and develop a

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
STAT1 min read
USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
STAT1 min read
Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.

Related Books & Audiobooks